WuXi AppTec expands to create a center of excellence in San Diego

By Melissa Fassbender contact

- Last updated on GMT

(Image: Getty/s-c-s)
(Image: Getty/s-c-s)

Related tags: Wuxi apptec, Small molecule, Manufacturing, Pharmacology, discovery services

The expansion collates WuXi AppTec’s technology platform small molecule capabilities, including screening, discovery biology, pharmacology, and process R&D.

The San Diego, CA-based facility – now a new center of excellence – also provides Phase I good manufacturing practice (GMP) manufacturing services.

WuXi AppTec​ Chairman and CEO Dr. Ge Li said the expansion will enable the company to better serve its US and global customers.

"Together with our ecosystem partners, we will continue to strengthen WuXi's capability and technology enabling platform to expedite the discovery and development of new medicines for patients worldwide,”​ Li said in a press release.

As part of the expansion, the contract research organization (CRO) also plans to hire “extensively”​ from around the San Diego area.

WuXi AppTec was unable to provide any further comment.

IPO and expansion

To build and expand its R&D facilities, the company earlier this year raised more than $353​ in an initial public offering (IPO) of common stock.

WuXi AppTec's IPO of 104,198,600 shares of common stock was offered on the Shanghai Stock Exchange at RMB21.60 per share. This, equivalent to US$3.39 per share, means the IPO has brought in more than $353m.

The company has completed expansions at several of its subsidiary companies, including STA Pharmaceutical​.

Related news

Show more

Related products

show more

Laboratory Solutions for COVID-19 Clinical Trials

Laboratory Solutions for COVID-19 Clinical Trials

Q2 Solutions | 10-Jun-2020 | Clinical Study

As a leading laboratory services organization for trials across the globe, we are proud to partner with clients to support COVID-19 clinical trials. Our...

Parents as Gatekeepers for Children with Cancer

Parents as Gatekeepers for Children with Cancer

PRA Health Sciences | 08-Jun-2020 | Technical / White Paper

The RACE for Children Act will require new drugs intended for adult cancer treatment to also be studied in pediatric cancers when the molecular target...

Related suppliers

Follow us


View more